News

Filter

Current filters:

Sprycel

1 to 9 of 54 results

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

UK Cancer Drugs Fund to re-assess procedure and currently-approved drugs

13-11-2014

The UK’s National Health Service has updated its procedure for evaluating drugs in the Cancer Drugs…

AvastinKadcylaOncologyPharmaceuticalRegulationSprycelUK

Indian Health Ministry seeking compulsory license for B-MS’ Sprycel

Indian Health Ministry seeking compulsory license for B-MS’ Sprycel

19-08-2014

Anti-leukemia drug dasatinib, made by US pharma major Bristol-Myers Squibb and sold in India under the…

Bristol-Myers SquibbDasatinibIndiaOncologyPatentsPharmaceuticalSprycel

Bristol-Myers Squibb releases strong third quarter results

Bristol-Myers Squibb releases strong third quarter results

23-10-2013

Bristol-Myers Squibb has announced strong third quarter results with sales up 9% to $4.1 billion.

BaracludeBristol-Myers SquibbFinancialNorth AmericaOnglyzaOrenciaPharmaceuticalSprycelYervoy

CML drug revenue in Japan to grow, despite global decline, says GlobalData

21-05-2013

Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

1 to 9 of 54 results

Back to top